MedTrace Logo

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)

NCT06834152 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-02-09

No results posted yet for this study

Summary

The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and/or prostatic hyperplasia.

Conditions

  • Localized Prostate Carcinoma
  • Prostate Cancer (Adenocarcinoma)
  • Prostate Hyperplasia
  • Lower Urinary Track Symptoms

Interventions

RADIATION

radiotherapy

Patients with prostate cancer in the medium or high risk range who are planned to receive definitive CT or MRI-adaptive SBRT.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Matthias Guckenberger, Prof. Dr. med. · University of Zurich

  • Tiuri E. Kroese, MD, PhD · University of Zurich

  • Matthias Guckenberger · University of Zurich

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-09-01
Completion
2031-06-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834152 on ClinicalTrials.gov